Novartis Prepares for UK Luxturna Rollout After Rapid NICE OK

Novartis/Spark’s gene therapy Luxturna has been OKd for NHS use by NICE in record time thanks to early engagement and close collaboration between the two parties. 

Eye
NICE has OKd Luxturna for a rare eye disorder

More from Drug Pricing

More from Scrip